ClinicalTrials.Veeva

Menu

Prospective Prevalence and Validation Study of Pediatric Intensive Care Delirium.

Rigshospitalet logo

Rigshospitalet

Status

Completed

Conditions

Pediatric Delirium

Treatments

Diagnostic Test: SOS-PD

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT04774211
NNF20OC0066074

Details and patient eligibility

About

Pediatric delirium (PD) is a poorly investigated clinical problem that needs to be further explored in a Danish context. Children are at risk of discomfort and suffering if they experience delirium. The condition is associated with prolonged mechanical ventilation, longer hospital stay, increased mortality, and risk of long-term cognitive impairment. Therefore, it is important to assess critically ill children with a validated tool to enable early detection and management of the condition. In this study, the investigators will determine the prevalence of pediatric intensive care delirium. To this end, the investigators will validate the Sophia Observation withdrawal Symptoms - Pediatric delirium scale (SOS-PD) for patient assessment.

Full description

Prospective prevalence and validation study of pediatric intensive care delirium.

Aim: To validate the SOS-PD assessment tool and determine the prevalence of delirium in children aged 3 months to 18 years in a Danish context.

Data analysis and power calculation: With 140 patients, the accuracy estimate in this study will have a 95% confidence interval of +/- 5%. Accuracy defined as (true positive + true negative) / all x 100 is expected to be 90%. The validity of the SOS-PD assessment tool is calculated from standard definitions of sensitivity, specificity, positive predictive value and negative predictive value. The prevalence is calculated in percent. All data will be entered and encoded in RedCap and exported to SPSS for statistical analysis of data.

Enrollment

141 patients

Sex

All

Ages

3 months to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pediatric intensive care patients
  • Length of stay of 48 hours or more

Exclusion criteria

  • Non Danish speaking
  • Use of neuromuscular blocking agents
  • sedation level at COMFORT behavior score > 11 or Richmond Agitation Sedation Scale > -3

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems